Ocular Complications Following Autologous Fat Injections into Facial Area
Case Report of a Recovery from Visual Loss After Ophthalmic Artery Occlusion and a Review of the Literature
Authors: Alexandra Szantyr, Michal Orski, Cracowia, Poland
Abstract With the increase in popularity of the use of cosmetic fillers in plastic and esthetic surgery, the possi- bility of severe ocular complications should not be neglected. Of the fillers used, autologous fat is the most common to cause permanent visual deterioration, one of the most severe complications associated with the use of cosmetic fillers. Here we present the first report of a complete recovery of visual acuity from an instance of visual loss with no light perception caused by ophthalmic artery occlusion of the right eye following autologous fat injection in the facial area. Immediate ophthalmological intervention and comprehensive therapy with pros- taglandins and vinpocetine made it possible to restore retinal perfusion and achieve complete recovery of visual acuity. Awareness of the iatrogenic artery occlusions associated with facial fillers and the need for immediate treatment should be popularized among injectors to prevent devastating consequences, such as permanent vision loss. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Keywords Vision loss · Blindness · Facial fillers · Filler injection · Autologous fat
With the increase in popularity of the use of cosmetic fillers in plastic and esthetic surgery, the possibility of severe ocular complications should not be neglected. Permanent visual deterioration, one of the most severe complications associated with the use of cosmetic fillers, can be the result of ophthalmic artery occlusion (OAO), generalized poste- rior ciliary artery occlusion (generalized PCAO) with rel- ative sparing of the central retinal artery, central retinal artery occlusion (CRAO), localized PCAO, branch retinal artery occlusion (BRAO) and posterior ischemic optic neuropathy (PION). Another classification includes diffuse occlusions (OAO, generalized PCAO, CRAO) and local- ized occlusions (localized PCAO, BRAO, PION) [1, 2]. Autologous fat injections are associated with diffuse occlusions, such as OAO  and central retinal artery occlusion , and are therefore characterized by more severe clinical symptoms and poorer visual prognosis when compared to other facial fillers. The proposed underlying mechanism assumes intravascular injection and retrograde embolization of the filler, as the injected bolus may over- come arterial pressure and move against the direction of blood flow [3, 4]. When the injector releases the plunger, the filler travels with blood flow and enters the ophthalmic artery and its branches. With higher injection pressures, filler particles may be pushed further retrograde and enter the brain circulation, which in turn results in cerebral infarction. Autologous fat is the most common filler type to cause iatrogenic blindness, being responsible for almost
48% of the cases of cosmetic filler-induced visual loss reported in the literature up to the present . Ocular complications occur most frequently after injection to the glabellar area, nasal region, nasolabial fold and forehead. However, due to the complex vascular anatomy of the face, essentially any location of the facial region may be at risk of ocular complications. Ocular symptoms most commonly include: sudden unilateral vision loss, ocular pain and headache, which are most likely to occur immediately after injection. Visual loss may be accompanied by ophthal- moplegia and ptosis [2, 3, 5, 6]. Although recovery from ophthalmoplegia and ptosis is observed in the majority of cases, vision loss is usually permanent. From 47 cases of ocular complications following autologous fat injections reported in the English language literature up to 2015, 38 cases resulted in complete vision loss . In 5 cases, some remaining visual acuity was observed, varying from light perception to 20/40 at follow-up, but no improvement was observed in any of the reported cases, despite the appli- cation of various management strategies . Although several treatment options have been proposed and reported [1, 2, 5, 6], until now no treatment has been proved to be effective. As results are usually unsatisfactory, there is little to no evidence for improvement with any proposed treatment. Therefore, we present here a report of a case of visual acuity recovery from complete visual loss with no light perception caused by ophthalmic artery occlusion of the right eye following autologous fat injection in the facial area.
A 38-year-old male with a posttraumatic defect of the squamous part of the forehead bone underwent soft tissue augmentation with autologous fat injection in his left supraorbital and right forehead area. Two years earlier, the patient had been hit by a piece of wood during work and suffered a bilateral fracture of the anterior cranial fossa and bilateral naso-orbital fracture. He underwent microplate osteosynthesis of the naso-orbital fractures as well as repair of the dura mater of the anterior cranial fossa. Eighteen months after the accident, the patient received his first autologous fat injection into his right forehead and supraorbital area with no intraoperative or postoperative complications. The patient was content with the esthetic results of the first procedure and wanted a second one to improve the results. The procedure was performed under local anesthesia (lidocaine with norepinephrine) with Byron Medical instrumentation. After infiltration of the donor’s abdominal area with the LAMISTM Infiltration Cannula (14 ga outer diameter, 30 cm length), autologous fat was harvested with COLEMANTM Aspiration Cannula (11 ga outer diameter, 15 cm length) using the lipoaspi- ration technique and prepared with the standard procedure. Fat was subcutaneously injected with the COLEMANTM Style Mini Infiltration Cannula (20 ga outer diameter, 3.175 cm length) and a 2-ml injecting syringe. Through two small incisions in the right forehead and supraorbital area, 5 ml of fat was injected into the left supraorbital area and 5 ml into the right forehead area. No scar release maneuvers were performed. During the injection of the final 0.5 ml of fat into the right forehead area, the patient reported ocular pain and flashes of light in front of the right eye, followed by a complete visual loss with no light perception in the right eye. Since occlusion of the right ophthalmic artery was suspected, the patient was immedi- ately transferred to the Ophthalmology Ward. On exami- nation, no light perception and a relative afferent pupillary defect in the right eye were observed. Fundus examination of the right eye showed pale, diffused edema of the retina and severely narrowed retinal arterioles with poor perfu- sion. Multiple shiny particles were observed within the lumen of the arteries, consistent with fat embolism. Oph- thalmic artery occlusion of the right eye was diagnosed. Treatment was administered immediately. The time from the first symptoms to the beginning of treatment was less than 20 min. The administered treatment included pro- longed circular digital and contact lens-induced ocular massage, ocular drops: 0.5% timolol, brimonidine and dorzolamide to the right eye, 24 mg dexamethasone intravenously, 500 ml of 20% mannitol intravenously, 80 ml of 40% glycerol per os, 500 mg of acetazolamide per os. Computed head tomography with contrast did not reveal any new pathologies apart from the preexisting fluid hypodense areas localized in the right frontal lobe with the partial defect of the squamous part of the forehead bone caused by the prior trauma. Slow visual recovery was observed within 90 min. Examination of the fundus of the right eye performed after 150 min from the first symptoms revealed patchy areas of retinal edema and partially per- fused retinal arteries. At that time, the patient reported multiple irregular visual field deficits. Further treatment included alprostadil (Prostavasin) 40 mcg administered intravenously (with the mean arterial pressure assessment every 15 min during the intravenous infusion) once a day for 6 days, dexamethasone intravenously in decreasing dosages scheme (2 9 8 mg on the second day, 3 9 4 mg on the third day, 3 9 2 mg on the fourth day).
The patient was discharged on the sixth day after the visual loss in good local and general condition. The best corrected visual acuity in the right eye improved to 0.1 logMAR. The standard automated perimetry showed irregular visual field deficits, and optical coherence tomography (OCT) revealed significant damage to the ganglion cell complex (GCC). Pharmacotherapy, with oral 5 mg vinpocetine daily, was continued after discharge. In the 2-year follow-up, visual acuity has remained stable, visual field examination has shown no visual deficits, and OCT has shown no further decrease in GCC.
Visual loss is one of the most severe complications reported in patients undergoing facial filler injections. In the majority of reported cases, visual deterioration was severe and irreversible [2, 5, 7]. Autologous fat injections are associated with the most severe visual impairment [2, 5, 8, 9]. Due to differences in particle size among the different types of facial fillers, patients with ocular symp- toms following other types of fillers, e.g., hyaluronic acid injections, are more likely to suffer from localized ocular occlusion with milder clinical manifestations and better visual prognosis than patients who received autologous fat injections [5, 8–10]. Preventative strategies proposed in the literature to reduce the risk of vascular complications fol- lowing facial filler injections include: using small-diameter blunt flexible cannulas or non-traumatic blunt tip needles instead of sharp cannulas and needles, limiting syringe size to 1 ml, aspirating before injection, injecting the filler slowly with minimal pressure, limiting the amount of filler to less than 0.1 ml with each pass, mixing the filler with vasoconstrictor, using a topical vasoconstrictor before injection and moving the needle tip while injecting [5, 7, 11, 12]. Avoiding injection at the sites of previous trauma, or at sites with chronic inflammation or scarring, is also advised. Facial filler injections in patients who have previously undergone facial or plastic surgeries should be performed with extra caution [5–7].
According to the literature, no fully effective treatment is available. Nevertheless, there are several papers pre- senting various treatment modalities that recover some degree of visual function. The aim of the treatment after facial filler embolism is to restore the perfusion of the retina as soon as possible. The retina is very sensitive to hypoxia, and after 90 min damage due to retinal ischemia becomes permanent [1, 3, 5, 7, 13]. Most previously reported cases of vision loss secondary to fat embolism have remained without any improvement. Therefore, no evidence-based treatment strategies are available. Slightly better outcomes have been reported in cases of vision loss following injection of fillers other than autologous fat [5, 7]. From 23 cases of ocular complications following injections of hyaluronic acid into the facial area, permanent vision loss was observed in 9 cases, and in 6 cases some level of improvement in visual acuity was reported . Treatment is aimed at lowering intraocular pressure to boost retinal perfusion, dilating arteries to eliminate embolus and reducing the inflammatory component of the injury. To decrease intraocular pressure, eye drops are administered (e.g., alpha agonists, B-blockers, carbonic anhydrase inhibitors) and ocular massage and anterior chamber paracentesis are performed. Carbon dioxide and oxygen inhalation or vasodilatory agents such as pros- taglandin E1 provoke arterial dilation. Hyperbaric oxygen therapy and systemic corticosteroids decrease the inflam- matory response. [1–3, 5, 6, 13]. Table 1 presents the currently recommended treatments and their underlying mechanism of action.
The crucial factor in the management strategy is the immediate assessment and referral to the specialist in the nearby area, preferably an ophthalmologist or retina spe- cialist, to start the proper treatment within the 90-min time span after which the damage to the retina is irreversible [10, 13]. Loh et al.  have proposed a treatment algo- rithm for managing vision loss following filler injections. When a patient presents the first symptoms of vascular compromise in the retina, filler injection should be instantly stopped and the patient should be laid in a supine position. Immediate treatment (including topical instilla- tion of timolol, and/or oral acetazolamide and ocular massage) should be administered by a non-ophthalmologist injector before arranging and transferring the patient to a specialist for a definitive therapy, which consists of further medical administration and—when indicated—anterior chamber paracentesis. In cases of hyaluronic acid-induced vision loss, hyaluronidase may be used to dissolve hya- luronic acid emboli [1–14]. After these acute measures have been taken, additional supportive therapy (corticos- teroids, hyperbaric oxygen therapy, anticoagulants) should be introduced to protect retinal cells.
In our case, treatment was started within 20 min of the first symptoms of vision loss. The successful outcome can also be ascribed to the comprehensiveness of the treatment aimed at restoring perfusion of the retina with the use of multiple drugs and management strategies. In previously reported cases, the treatment provided has usually been incomplete, since the majority of patients suffering from ocular complications received at most a 3-step therapy [6, 7]. As noted by Chen et al. , combination therapy may contribute to recovery of visual symptoms. In our case, in addition to commonly used treatment options such as ocular massage, acetazolamide, mannitol and corticos- teroids, we also used alprostadil and vinpocetine. Alpros- tadil is a synthetic variant of prostaglandin E1. It causes vasodilatation through directly affecting the vascular smooth muscles and increases blood flow in the retina. Alprostadil also decreases thrombocyte activation, improves cell metabolism by increasing oxygen supply to the tissues and decreases neutrophil activation and the release of their toxic metabolites, helping to reduce tissue damage caused by inflammation and possibly by hypoxia. The use of prostaglandin E1 as a part of comprehensive therapy for visual loss following hyaluronic acid injection was also reported by Chen et al.  and resulted in improvement in visual acuity, extraocular movement and visual field defects. Vinpocetine, chemically known as ethyl apovincamine, is a vinca alkaloid that increases cerebral blood flow and has neuroprotective effects . This drug is used in the treatment of ischemic cere- brovascular diseases and vascular dementias. Vinpocetine may help to increase retinal perfusion and prevent further damage to still-viable central retinal tissue.
The common use of facial injections, most often performed in esthetic medicine, has resulted in an increased number of ocular complications. In the presented case, after autolo- gous fat injection the patient suffered from sudden com- plete vision loss in one eye. Fundus examination and specific symptoms enabled a diagnosis of ophthalmic artery occlusion. Immediate ophthalmological intervention and comprehensive therapy with prostaglandins and vin- pocetine made it possible to restore retinal perfusion and achieve complete recovery of visual acuity. Awareness of iatrogenic artery occlusions associated with facial fillers and the need for immediate treatment should be popularized among injectors to prevent devastating con- sequences such as permanent vision loss.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest to disclose.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
1. Hwang JC (2016) Periorbital Injectables: understanding and Avoiding Complications. J Cutan Aesthet Surg 9(2):73–79
2. Park SW, Woo SJ, Park KH (2012) Iatrogenic retinal artery occlusion caused by cosmetic facial filler injections. Am J Oph- thalmol 154:653–662
3. DeLorenzi C (2014) Complications of injectable fillers, part 2: vascular complications. Aesthet Surg J 34(4):584–600
4. Li X, Du L, Lu JJ (2015) A novel hypothesis of visual loss secondary to cosmetic facial filler injection. Ann Plast Surg 75(3):258–260
5. Belezenay K, Humphrey K, Humphrey S, Jones D (2015) Avoiding and treating blindness from fillers: a review of the world literature. Dermatol Surg 41(10):1097–1117
6. Lazzeri D, Agostini T, Figus M, Nardi M et al (2012) Blindness following cosmetic injections of the face. Plast Reconstr Surg 129:994–1012
7. Chen W, Wu L, Jian XL, Zhang B, Li JY, Qin XL, Yu B (2016) Retinal branch artery embolization following hyaluronic acid injection: a case report. Aesthet Surg J 36(7):219–224
8. Park KH, Kim YK, Woo SJ et al (2014) Iatrogenic occlusion of the ophthalmic artery after cosmetic facial filler injections: a national survey by the Korean Retina Society. JAMA Ophthalmol
9. Carruthers JD, Fagien S, Rohrich RJ, Weinkle S, Carruthers A (2014) Blindness caused by cosmetic filler injection: a review of cause and therapy. Plast Reconstr Surg 134:1197–1201
10. Chen CS, Lee AW (2008) Management of acute central retinal artery occlusion. Nat Clin Pract Neurol 4:376–383
11. Coleman SR (2002) Avoidance of arterial occlusion from injec- tion of soft tissue fillers. Aesthet Surg J 22:555–557
12. Yoshimura K, Coleman SR (2015) 0 Complications of fat grafting how they occur and how to find, avoid, and treat them. Clin Plast Surg 42:383–388
13. Loh KT, Chua JJ, Lee HM, Lim JT, Chuah G, Yim B, Puah BK (2016) Prevention and management of vision loss relating to facial filler injections. Singap Med J 57(8):438–443
14 Rumelt S, Dorenboim Y, Rehany U (1999) Aggressive systematic treatment for central retinal artery occlusion. Am J Ophthalmol 128(6):733–738
15 Li X, Du L, Lu JJ (2015) A novel hypothesis of visual loss sec- ondary to cosmetic facial filler injection. Ann Plast Surg 75(3):258–260
16 Patyar S, Prakash A, Modi M, Medhi B (2011) Role of vin- pocetine in cerebrovascular diseases. Pharmacol Rep 63(3):618–628